Preparation of a HMG-CoA Reductase Inhibitor via an Optimized Imidazole-Forming Condensation Reaction
Authors:
- 27 September 2008
- journal article
- research article
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 12 (6) , 1183-1187
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Statins and myotoxicity: a therapeutic limitationExpert Opinion on Drug Safety, 2006
- Incidence of Hospitalized Rhabdomyolysis in Patients Treated With Lipid-Lowering DrugsJAMA, 2004
- Familial Hypercholesterolemia and Coronary Heart Disease: A HuGE Association ReviewAmerican Journal of Epidemiology, 2004
- Current overview of statin-induced myopathyThe American Journal of Medicine, 2004
- Comparative Dose Efficacy Study of Atorvastatin Versus Simvastatin, Pravastatin, Lovastatin, and Fluvastatin in Patients With Hypercholesterolemia (The CURVES Study) fn1fn1This study was supported by Parke-Davis, Division of Warner Lambert Company, Morris Plains, New Jersey. Manuscript received August 20, 1997; revised manuscript received and accepted November 24, 1997.The American Journal of Cardiology, 1998
- Hydrophilicity/ lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitorsTrends in Pharmacological Sciences, 1998
- Primary prevention of coronary heart disease: role of cholesterol control in the United StatesJournal of Internal Medicine, 1997
- The convergent synthesis of CI-981, an optically active, highly potent, tissue selective inhibitor of HMG-CoA reductaseTetrahedron Letters, 1992
- Regiochemical aspects associated with the intramolecular 1,3-dipolar cycloaddition reactions of munchnone derivativesTetrahedron Letters, 1980